By Lisa Kerner
Charlotte, N.C., Oct. 9 - mtm laboratories AG said it completed a €22 million series C financing round.
Proceeds will be used to fund the clinical development and commercialization of proprietary diagnostic and screening devices for cervical cancer, according to a company news release.
HBM BioVentures and HBM BioCapital led the financing round, joined by a consortium including Heidelberg Innovation and Wellington Partners, plus new investors Nexus Medical Partners and SwissFirst Bank.
mtm laboratories is a privately held medical diagnostics company based in Heidelberg, Germany.
| Issuer: | mtm laboratories AG
|
| Issue: | Series C financing
|
| Amount: | €22 million
|
| Investors: | HBM BioVentures and HBM BioCapital (co-led), Heidelberg Innovation, Wellington Partners, Nexus Medical Partners, SwissFirst Bank
|
| Announcement date: | Oct. 9
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
